DEFA14A: Dynavax Defends Strategy Against Deep Track, Highlights Strong Financial Performance and Shareholder Returns

Dynavax urges stockholders to vote for its director nominees, highlighting strong financial results and shareholder returns, while criticizing Deep Track's proposed strategy as value-destructive.

Summary

• Dynavax has filed an investor presentation defending its strategy and board against Deep Track Capital's proposals.
• The presentation highlights Dynavax's successful pivot to its vaccine business, particularly HEPLISAV-B, which has led to significant shareholder returns.
• Dynavax reports a 203% total return to stockholders over the last five years, outperforming vaccine peers and the S&P Biotechnology Select Industry Index.
• HEPLISAV-B achieved $268 million in net product revenue in 2024 and approximately 44% U.S. market share.
• First quarter 2025 earnings show a 36% year-over-year increase in HEPLISAV-B net product revenue, reaching $65 million, and a 34% increase in total revenue to $68.2 million.
• The company generated over $950 million in net product revenue from 2020 to 2022 through its business development strategy during the pandemic.
• Dynavax has executed over 85% of its $200 million share repurchase program authorized in November 2024.
• The board has been proactively refreshed, with six of eight independent directors appointed since 2020.
• Dynavax criticizes Deep Track's plan to monetize HEPLISAV-B exclusively for capital return, calling it a flawed and myopic approach that jeopardizes long-term growth.
• Deep Track rejected four settlement proposals due to its demand for board representation and implementation of its strategy.
• Dynavax's board recommends stockholders vote for its director nominees on the GOLD proxy card.

Sentiment

Score: 7

Explanation: The document presents a confident and positive outlook on Dynavax's performance and strategy, while also addressing potential risks and challenges. The strong financial results and shareholder returns contribute to the positive sentiment, but the ongoing proxy battle introduces some uncertainty.

Positives

• Dynavax has demonstrated strong financial performance with HEPLISAV-B.
• The company has delivered significant returns to stockholders.
• Dynavax has a proactive and strategic board refreshment plan.
• The company has a successful track record of business development during the pandemic.
• Dynavax is returning capital to stockholders through a share repurchase program.

Negatives

• Deep Track believes Dynavax should focus on monetizing HEPLISAV-B and returning capital to shareholders, which Dynavax management believes is a flawed strategy.
• Deep Track rejected four settlement proposals, indicating a potential lack of compromise.

Risks

• The company faces risks related to commercializing and supplying HEPLISAV-B.
• Market size or actual demand for Dynavax's products may differ from expectations.
• The company faces risks related to the timing of completion and results of current clinical studies.
• There are risks related to the development and testing of vaccines containing CpG 1018 adjuvant.
• The company faces risks related to the implementation of its long-term growth objectives.

Future Outlook

The company aims to continue delivering value for stockholders, increase market share, and execute its long-term growth objectives.

Management Comments

• The Dynavax Board of Directors is committed to acting in the best interests of all stockholders.
• The Board unanimously recommends that stockholders vote FOR all four of Dynavaxs director nominees.

Industry Context

The document highlights Dynavax's outperformance compared to vaccine peers and the S&P Biotechnology Select Industry Index, suggesting a strong competitive position within the biopharmaceutical industry.

Comparison to Industry Standards

• Dynavax's 203% total return to stockholders over the last five years significantly outperforms the 9% return of vaccine peers and the -17% return of the S&P Biotechnology Select Industry Index.
• The company's HEPLISAV-B vaccine has achieved a 44% U.S. market share, indicating a leading position in the hepatitis B vaccine market.
• The document does not provide specific comparisons to individual companies, but the general outperformance metrics suggest a strong competitive standing.

Corporate Governance

Stakeholder Impact

• Stockholders are impacted by the company's financial performance, capital allocation strategy, and the outcome of the proxy vote.
• Employees are impacted by the company's business strategy and potential changes to the board.
• Customers (patients) are impacted by the continued availability and market position of HEPLISAV-B.

Next Steps

• Stockholders are urged to vote on the GOLD proxy card for Dynavax's director nominees.
• The 2025 Annual Meeting of Stockholders will be held on June 11, 2025.

Key Dates

Keywords

Dynavax, HEPLISAV-B, vaccine, proxy statement, Deep Track, shareholder, board, revenue, stockholders, director nominees